Inhibitors in haemophilia: Clinical aspects

Haemophilia, Supplement

Volumn 10, Issue 4, 2004, Pages 140-145

  DiMichele, D ^a   Rivard, G ^b   Hay, C ^c   Antunes, S ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immune tolerance; Inhibitor prevention; Inhibitor risk factors; Inhibitor therapy

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; TRANEXAMIC ACID;

ANTIBODY PRODUCTION; ARTICLE; BREAST FEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG SUBSTITUTION; ETHNOLOGY; FAMILY HISTORY; GENE DELETION; GENE REARRANGEMENT; GENETIC SUSCEPTIBILITY; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEMARTHROSIS; HEMOPHILIA; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFANT; MORBIDITY; MORTALITY; ORAL BLEEDING; PATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

EID: 11044235586     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00993.x     Document Type: Article

References (29)

1. Oldenburg J, Tuddenham E. Genetic basis of inhibitor development in severe haemophilia A and B. In: Rodriguez-Merchan EC, Lee CA, eds. Inhibitors In Patients With Haemophilia. Oxford: Blackwell Publishing. 2002: 21-6.
2. Astermark J, Berntorp E, White GC, Kroner BL, MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
3. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. In: Hoyer, LW, ed. Factor VIII Inhibitors New York: Liss. 1984: 19-28.
4. Addiego JE Jr, Kasper C, Abildgaard C et al. Increased frequency of inhibitors in African American hemophilia A patients. Blood 1994; 1 (Suppl.): 239a.
5. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Blood Coagul Fibrinolysis Cell Haemost 2003: 475-9.
6. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
7. von Auer C, Oldenburg J, Auerswald G, von Depka-Prodzinski M, Eifrig B. Escuriola-Ettinghausen et al. The development of inhibitors directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A. J Thromb Haemost 2004; 1 (Suppl.): P1623 (Abstract).
8. DiMichele D, Rothschild C, Sultan Y, Kroner B, Aledort L, Members of the ISTH FVIII/IX Subcommittee. Multicenter comparison of inhibitor (INH) development on plasma-derived (pd) vs. recombinant (rec) factor VIII (FVIII) in severe hemophilia A patients (sHA Pts). Blood 1999, 2003; 1 (Suppl.): 238a.
9. Knobe KE, Sjorin E, Tengborn LI, Petrini P, Ljung RCR. Inhibitors in the Swedish population with severe haemophilia A and B. a 20-year survey. Acta Paediatr 2002: 910-4.
10. Rothschild C, Goudemand J, Demiguel V, Lambert T, Calvez T. Effect of type of treatment (recombinant vs. plasmatic) on FVIII inhibitor incidence according to known risk cofactors in previously untreated severe hemophilia A patients (Pups). J Thromb Haemost 2003; 1 (Suppl.): Abstract OC215.
11. Kreuz W, Ettinghausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003, 2003; 88: EREP04.
12. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
13. Mauser-Bunschoten EP, Niewenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
14. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years of the Bonn Protocol. Vox Sang 1996; 70 (Suppl.): 30-5.
15. Mariani G, Ghirardini A, Bellocoo R. Immunetolerance in hemophilia: principal results from the international registry. Thromb Haemost 1994; 72 (1): 155-8.
16. DiMichele DM, Kroner B. and the North American Immune Tolerance study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87 52-7.
17. Kroner BL. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sang 1999; 77 (Suppl. 1): 33-7.
18. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemopbilia 1998; 4: 574-6.
19. Warrier I, Lenk H, Saidi P, Pollman H, Tengborn L, Berntorp E. Nephrotic syndrome in hemophilia B patients with inhibitors. Haemopbilia 1998; 4: 248-51.
20. Darby SC, Keeling DM, Spooner RJD, et al. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality. J Thromb Haemost 2004: May, in-press, 1977-99.
21. Hilgartner M. Makipernaa, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemopbilia 2003; 9: 261-8.
22. Brackmann HH, Effenberger E, Hess R, Schwaab R, Oldenburg J. Novoseven in immune tolerance therapy. Blood Coagul Fibrin 2000; 11 (Suppl. 1): S39-S44.
23. DiMichele D. Immune tolerance therapy dose as an outcome predictor. Haemophilia 2003; 9: 382-6.
24. Srivasta A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474-80.
25. Antunes SV. Haemophilia in the developing world: the Brazilian experience. Haemophilia 2002; 8: 199-204.
26. Fontes EM, Amorim L, Carvalho SM, Farah MB. Hemophilia care in the state of Rio de Janeiro, Brazil. Rev Panam Salud Publica 2003; 13: 124-8.
27. Mannucci PM. Hemophilia: Treatment options in the twenty-first century. J Thromb Haemost 2003; 1: 1349-55.
28. Yee TT, Lee CA. Oral immune tolerance induction to factor VIII via breast milk, a possibility? Haemophilia 2000; 6: 591.
29. Knobe KE, Tengborn LI, Petrini P, Ljung RCR. Breast-feeding does not influence the development of inhibitors in haemophilia. Haemophilia 2002; 8: 657-9.